India gives emergency use authorisation for needle-free vaccine ZyCoV-D in COVID-19. | medthority.com
ZyCoV-D is a three dose vaccine which will be administered first on day zero, day 28th and then on the 56th day. With this approval, India now has its first COVID-19 vaccine for the adolescents in the 12-18 age group, besides the adult population. ZyCoV-D, is a needle-free vaccine administered using The PharmaJet a needle free applicator, which ensures painless intradermal vaccine delivery.
ZyCoV-D is an intradermal vaccine, which will be administered in three doses. It will be applied using The PharmaJet needle free system, Tropis, which can also lead to a significant reduction in any kind of side effects. ZyCoV-D is stored at 2-8 degree C but has shown good stability at temperatures of 25 degree C for at least three months. The plasmid DNA platform provides ease of manufacturing with minimal biosafety requirements (BSL-1). Also being a Plasmid DNA vaccine, ZyCoV-D doesn't have any problem associated with vector based immunity. The Plasmid DNA platform also allows generating new constructs quickly to deal with mutations in the virus, such as those already occurring. The results of the Phase I part of the Phase I/II clinical trial have already been published in the EClinical Medicine Journal of Lancet.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins